BridgeBio Oncology Therapeutics, Inc.
BBOTNasdaqCIK 1869105HealthcareFiscal year ends Dec 31
Reports and events: 39 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0820:19 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385225 |
| 2026-08-1120:12 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344661 |
| 2026-08-1120:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344608 |
| 2026-07-0620:37 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-075546 |
| 2026-06-2220:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-277513 |
| 2026-05-1221:11 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219829 |
| 2026-05-1221:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219801 |
| 2026-04-2920:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-191512 |
| 2026-04-2820:06 ET | DEF 14A | Proxy statementPeriod 2026-06-16 | 0001193125-26-186944 |
| 2026-04-2321:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-170888 |
| 2026-03-2620:52 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-126493 |
| 2026-03-0521:40 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-094112 |
| 2026-03-0521:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093997 |
| 2026-01-0712:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005425 |
| 2025-11-1221:52 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277834 |
| 2025-11-1221:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277601 |
| 2025-08-2920:08 ET | S-1 | Registration statement | 0001193125-25-192760 |
| 2025-08-1821:41 ET | SCHEDULE 13D | Ownership report, active investor | 0001193125-25-182790 |
| 2025-08-1312:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-25-075307 |
| 2025-08-1300:54 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 4.01 Change of auditor; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 5.06 Item not in the standard list; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-075190 |
| 2025-08-0611:34 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-072312 |
| 2025-08-0420:45 ET | 8-K | 5.07 Shareholder vote results | 0001213900-25-071392 |
| 2025-08-0120:47 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001213900-25-070659 |
| 2025-07-1111:44 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-062955 |
| 2025-05-1521:26 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001213900-25-044424 |
| 2025-03-1100:31 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001213900-25-022387 |
| 2025-03-0423:43 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-25-020316 |
| 2025-03-0302:56 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-25-018997 |
| 2025-02-2813:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-018334 |
| 2025-02-1011:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-25-011454 |
| 2024-11-1421:30 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001213900-24-098483 |
| 2024-08-1412:47 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001213900-24-068630 |
| 2024-05-1520:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001213900-24-043582 |
| 2024-02-2000:48 ET | SC 13D | Ownership report, active investor | 0001213900-24-015480 |
| 2024-02-2021:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-015329 |
| 2024-02-1412:35 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-013637 |
| 2024-02-0702:18 ET | S-1/A | Registration statement, amended | 0001213900-24-010676 |
| 2024-02-0218:04 ET | S-1/A | Registration statement, amended | 0001213900-24-009481 |
| 2024-01-1822:24 ET | S-1 | Registration statement | 0001213900-24-004590 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.